TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00844740
Drug: Cinacalcet
Normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
Study: NCT03720418
Drug: OXB-102
Normalized name: Oxbryta
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neurosurgical delivery of OXB-102 (gene therapy) to the putamen
Study: NCT01108458
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: iv, 840 mg, 420 mg
Study: NCT01108458
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO, 150 mg
Study: NCT02556437
Drug: HyQvia
Normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
Study: NCT00792558
Drug: BMS-817378
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
Study: NCT01303120
Drug: Femoral Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot
Study: NCT01303120
Drug: Combined nerve blocks
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative Bupivacaine 0.5%, perineurally as single shot
Study: NCT00231673
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
Study: NCT02912455
Drug: canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: encapsulated (gelatin capsule).
Study: NCT01845337
Drug: Teysuno
Normalized name: Teysuno
DrugBank: Gimeracil (DB09257)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01712308
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004759
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004759
Drug: tirilazad
Normalized name: TIRILAZAD
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04505202
Drug: 0.12% chlorhexidine gluconate
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients included in the experimental group (0.12% chlorhexidine gluconate) will receive 3 times daily oral care
Study: NCT04872244
Drug: Levonorgestrel Drug Implant Product
Normalized name: levonorgestrel Drug Implant Product
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrauterine administration
Study: NCT03328143
Drug: Lavender (Lavandula angustifolia)
Normalized name: lavender (Lavandula angustifolia)
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender (Lavandula angustifolia) is an essential oil.
Study: NCT03738449
Drug: CKD-387
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT03738449
Drug: D484
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: reference drug
Study: NCT03736343
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will complete two drinking sessions.
Study: NCT00649363
Drug: Ondansetron Orally Disintegrating Tablets 8 mg
Normalized name: ondansetron Disintegrating Oral Tablet
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg, single dose fasting
Study: NCT01807156
Drug: Tivozanib
Normalized name: Tivozanib
DrugBank: Tivozanib (DB11800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral medication given daily. No placebo.
Study: NCT02012192
Drug: Ganetespib
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02012192
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00122590
Drug: nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00122590
Drug: lopinavir/r
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Lopinavir (DB01601)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00122590
Drug: indinavir
Normalized name: Indinavir
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00122590
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01074892
Drug: Provera (medroxyprogesterone/progestin)
Normalized name: medroxyprogesterone Oral Tablet [Provera]
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
Study: NCT01074892
Drug: Provera (medroxyprogesterone)
Normalized name: medroxyprogesterone Oral Tablet [Provera]
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg per oral tablet. One tablet per day for 6 months
Study: NCT02237235
Drug: MMFS-202-302
Normalized name: MMF
DrugBank: Monomethyl fumarate (DB14219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active ingredient: L-Threonic acid Magnesium salt.~1 g (2 pills) by mouth once daily in the evening for 9 weeks~Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt~1 g (2 pills) by mouth once daily in the morning for 9 weeks
Study: NCT00970216
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
Study: NCT03648554
Drug: dulaglutide (TRULICITY®) 1.5 mg
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dulaglutide (TRULICITY®) 1.5 mg subcutaneous administration, one weekly injection over 52 weeks of treatment
Study: NCT03559803
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
Study: NCT04192656
Drug: Methylprednisolone Hemisuccinate
Normalized name: Methylprednisolone hemisuccinate
DrugBank: Methylprednisolone hemisuccinate (DB14644)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone is the first-line treatment of idiopathic sudden sensorineural hearing loss
Study: NCT00757185
Drug: ganirelix acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
Study: NCT00757185
Drug: methyl testosterone
Normalized name: 7-beta,17-alpha-Dimethyl testosterone
DrugBank: Methyltestosterone (DB06710)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
Study: NCT03779178
Drug: Landiolol
Normalized name: Landiolol
DrugBank: Landiolol (DB12212)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Landiolol perfusion over 120 minutes in incremental doses : 0.5, 1, 2, 5 and 10 µg/kg/min. Doses are modified every 20 minutes
Study: NCT01833312
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti-shivering treatment
Study: NCT01833312
Drug: Pethidine
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti-shivering treatment
Study: NCT00192062
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00192062
Drug: vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02352987
Drug: Salicylic acid
Normalized name: Salicylic Acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
Study: NCT02450552
Drug: Ezogabine
Normalized name: Ezogabine
DrugBank: Ezogabine (DB04953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
Study: NCT04300452
Drug: Carbetocin
Normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Carbetocin after placental detachment
Study: NCT04300452
Drug: Ergometrine Maleate
Normalized name: Ergometrine maleate
DrugBank: Ergometrine (DB01253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of ergometrin after placental detachment
Study: NCT02710305
Drug: oral hyoscine butyl bromide tablets plus lidocaine cream
Normalized name: Butyl Alcohol
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
Study: NCT00007826
Drug: alum adjuvant
Normalized name: alum
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02412904
Drug: rFSH
Normalized name: rFSH-alpha
DrugBank: Follitropin (DB00066)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
Study: NCT00835328
Drug: Exendin (9-39)
Normalized name: EXENDIN (9-39)
DrugBank: Avexitide (DB14806)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A short-term intravenous infusion of the investigational drug, Exendin (9-39), will be administered over up to 9 hours.
Study: NCT03838575
Drug: 2% alcoholic chlorhexidine skin prep (SKIN PREP)
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention describes the preparation of the intact skin incision site immediately prior to incision, using chlorhexidine gluconate (CHG) in an alcohol-based solution, providing durable sterilisation of the surgical field. Pre-prepared applicators will be available for use in this trial (ChloraPrep™ sticks, 2% CHG with 70% isopropyl alcohol, BD Infection Prevention).
Study: NCT04181437
Drug: NVP-1203-R1
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet, Single oral dosing
Study: NCT04181437
Drug: NVP-1203-R2
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet, Single oral dosing
Study: NCT04181437
Drug: NVP-1203-R1 and NVP-1203-R2
Normalized name: NVP
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NVP-1203-R1,1 tablet and NVP-1203-R2, 1 tablet, co-administration, single oral dosing
Study: NCT00770133
Drug: Naphazoline
Normalized name: Naphazoline
DrugBank: Naphazoline (DB06711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
Study: NCT00770133
Drug: Ketotifen
Normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
Study: NCT03708588
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chewed
Study: NCT03708588
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integral
Study: NCT02093663
Drug: MMX Mesalamine/Mesalazine (Low Dose)
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily, tablets - the amount depends on the participants weight; 900 milligram per day (mg/day) for participants weighing 18 kg to less than or equal to (\<=) 23 kilograms (kg); 1200 mg/day for participants weighing greater than (\>) 23 kg to \<= 35 kg; 1800 mg/day for participants weighing \> 35 kg to \<= 50 kg; 2400 mg/day for participants weighing \> 50 kg to \<= 90 kg.
Study: NCT02093663
Drug: MMX Mesalamine/Mesalazine (High Dose)
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily, tablets - the amount depends on the participants weight;1800 mg/day for participants weighing 18 kg to \<= 23 kg; 2400 mg/day for participants weighing \> 23 kg to \<= 35 kg; 3600 mg/day for participants weighing \> 35 kg to \<= 50 kg; 4800 mg/day for participants weighing \> 50 kg to \<= 90 kg.
Study: NCT00247988
Drug: Weekly Taxotere with weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03396484
Drug: Methyldopa
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral dosing
Study: NCT01391325
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Study: NCT00981747
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20mg three times per day for 3 months followed by a one month washout prior to next intervention.
Study: NCT03240523
Drug: Vilaprisan (BAY1002670)
Normalized name: Vilaprisan
DrugBank: Vilaprisan (DB11971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, 2 mg, once daily
Study: NCT02910570
Drug: Liraglutide 3 mg (Saxenda)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
Study: NCT02910570
Drug: Liraglutide 3 mg placebo
Normalized name: liraglutide 3.6 MG/ML
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
Study: NCT01502137
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
Study: NCT01502137
Drug: somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
Study: NCT01554176
Drug: Filorexant
Normalized name: Filorexant
DrugBank: Filorexant (DB12158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filorexant, one 10 mg tablet, orally, once daily at bedtime
Study: NCT00981747
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 25mg two times a day for 3 months followed by a one month washout prior to next intervention.
Study: NCT02664922
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.
Study: NCT02664922
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.~1 of 2 sedation groups for VT ablation and afib procedures.
Study: NCT02664922
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 general anesthesia group for VT ablations and afib procedures.
Study: NCT00100009
Drug: TAC-PF
Normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00100009
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05287425
Drug: Ciprofloxacin Ophthalmic
Normalized name: ciprofloxacin ophthalmic
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 drops daily in both eyes for 7 ± 1 days
Study: NCT05287425
Drug: Povidone Ophthalmic
Normalized name: povidone ophthalmic
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops daily in both eyes for 7 ± 1 days
Study: NCT05287425
Drug: Povidone and Benzalkonium Chloride Ophthalmic
Normalized name: povidone Ophthalmic Solution
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 drops daily in both eyes for 7 ± 1 days
Study: NCT04061590
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04061590
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT04061590
Drug: Pemetrexed Disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT01492686
Drug: MCI-186 in open label phase
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
Study: NCT00079638
Drug: Niacin
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00079638
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00079638
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03182140
Drug: Kyleena
Normalized name: Kyleena
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Kyleena - intrauterine delivery system containing 19.5 mg LNG
Study: NCT00981747
Drug: Sildenafil and Losartan
Normalized name: losartan and amlodipine
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20mg three times per day and Losartan 25mg two times per day followed by a one month washout prior to next intervention.
Study: NCT01264354
Drug: Clevudine 30mg
Normalized name: zinc pyrithione
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 30mg
Study: NCT01264354
Drug: Clevudine 20mg+Adefovir dipivoxil 10mg
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clevudine 20mg+ Adefovir 10mg
Study: NCT01264354
Drug: Clevudine 20mg
Normalized name: zinc pyrithione
DrugBank: Clevudine (DB06683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clevudine 20mg
Study: NCT01722162
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02604173
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
Study: NCT02604173
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
Study: NCT00691873
Drug: Xolair
Normalized name: Xolair
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
Study: NCT04205344
Drug: Bupivacaine 5 mg
Normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 5 mg
Study: NCT04205344
Drug: Bupivacaine 10 mg
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receive subarachnoid hyperbaric bupivacaine at a dose of 10 mg
Study: NCT01131039
Drug: Gemcitabine/Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Gemcitabine: IV, days 1,8, and every 21 days~Bevacizumab: IV, day 1 and every 21 days until disease progression
Study: NCT01722162
Drug: Levocetirizine
Normalized name: Levocetirizine
DrugBank: Levocetirizine (DB06282)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00105222
Drug: Sodium Nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00669851
Drug: AI-700
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00181649
Drug: Recombinant human prolactin
Normalized name: prolactin
DrugBank: Prolactin G129R (DB18431)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01172964
Drug: flucytosine
Normalized name: Flucytosine
DrugBank: Flucytosine (DB01099)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02507843
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.